Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 33Cetuximab 16Cisplatin 10Radiotherapy 8Paclitaxel 8Docetaxel 8atezolizumab 7Fluorouracil 7cemiplimab 6Drug Therapy 6budigalimab 5Gemcitabine 5Cyclophosphamide 5Blood Specimen Collection 5trametinib 4Pemetrexed 4Nivolumab 4Magnetic Resonance Spectroscopy 4Bleomycin 4Bevacizumab 4palbociclib 3fludarabine 3durvalumab 3dabrafenib 3avelumab 3Trastuzumab 3Oxaliplatin 3Interleukin-2 3Indocyanine Green 3Immunotherapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × sotigalimab × Head & Neck × Clear all
NCT02482168 2023-12-20

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Apexigen America, Inc.

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryHead & Neck

Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡